X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (339) 339
index medicus (265) 265
male (217) 217
animals (211) 211
spiro compounds - therapeutic use (207) 207
female (183) 183
spiro compounds - pharmacology (173) 173
spiro compounds - adverse effects (161) 161
middle aged (134) 134
adult (124) 124
pharmacology & pharmacy (122) 122
spiro compounds - administration & dosage (100) 100
aged (89) 89
mice (79) 79
dose-response relationship, drug (68) 68
rats (65) 65
spiro compounds - chemistry (59) 59
double-blind method (55) 55
spiro compounds - pharmacokinetics (49) 49
treatment outcome (45) 45
administration, oral (42) 42
antineoplastic agents - adverse effects (42) 42
chemistry, medicinal (41) 41
analysis (40) 40
adolescent (38) 38
drug evaluation (37) 37
biochemistry & molecular biology (35) 35
oncology (35) 35
spiro compounds - toxicity (35) 35
structure-activity relationship (35) 35
double-blind (34) 34
schizophrenia - drug therapy (34) 34
spiro compounds - chemical synthesis (34) 34
clinical trials as topic (33) 33
cancer (32) 32
disease models, animal (31) 31
time factors (30) 30
toxicology (30) 30
molecular structure (28) 28
neurosciences (28) 28
research (28) 28
antineoplastic agents - therapeutic use (27) 27
spiro compounds (27) 27
young adult (27) 27
drug therapy (26) 26
efficacy (26) 26
indoles - pharmacology (24) 24
safety (24) 24
antidiuretic hormone receptor antagonists (23) 23
care and treatment (23) 23
chemistry, organic (23) 23
drug therapy, combination (23) 23
endocrinology & metabolism (23) 23
nausea - chemically induced (23) 23
vomiting - chemically induced (23) 23
chemotherapy (22) 22
morpholines - therapeutic use (22) 22
pharmacology (21) 21
fluspirilene - adverse effects (20) 20
germanium - adverse effects (20) 20
neoplasms - drug therapy (20) 20
toxicity (20) 20
drug discovery (19) 19
indoles - therapeutic use (19) 19
organometallic compounds (19) 19
pharmacokinetics (19) 19
rats, sprague-dawley (19) 19
aged, 80 and over (18) 18
apoptosis (18) 18
cell biology (18) 18
dogs (18) 18
indoles - adverse effects (18) 18
piperidines - adverse effects (18) 18
article (17) 17
health aspects (17) 17
microbiology (17) 17
prevention (17) 17
activation (16) 16
cell line (16) 16
drug design (16) 16
germanium - therapeutic use (16) 16
neurokinin-1 receptor antagonists - therapeutic use (16) 16
piperidines - therapeutic use (16) 16
receptors, opioid, kappa - agonists (16) 16
tranquilizing agents - adverse effects (16) 16
cell line, tumor (15) 15
in-vitro (15) 15
insecticides (15) 15
nausea (15) 15
parasitology (15) 15
potent (15) 15
rats, wistar (15) 15
spiro compounds - metabolism (15) 15
antiemetics - therapeutic use (14) 14
clinical trials (14) 14
hyponatremia - drug therapy (14) 14
infectious diseases (14) 14
malaria (14) 14
medicine & public health (14) 14
organometallic compounds - adverse effects (14) 14
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (478) 478
German (13) 13
French (8) 8
Japanese (6) 6
Italian (2) 2
Polish (2) 2
Russian (2) 2
Spanish (2) 2
Chinese (1) 1
Dutch (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Neuropharmacology, ISSN 0028-3908, 08/2013, Volume 71, pp. 83 - 97
Serotonin (5-HT) is a neurotransmitter that is involved in many behavioral functions, including the organization of defense, and its putative pathological... 
Fear | Zebrafish | Anxiety | Serotonin | Scototaxis | Geotaxis | 5-HYDROXYTRYPTAMINE RELEASE | RAT | 5-HT1A RECEPTOR ANTAGONISTS | REUPTAKE INHIBITORS | DORSAL RAPHE | ADULT ZEBRAFISH | ELEVATED PLUS-MAZE | T-MAZE | NEUROSCIENCES | IN-VIVO | PHARMACOLOGY & PHARMACY | BRAIN | Anti-Anxiety Agents - administration & dosage | Fenclonine - administration & dosage | Spiro Compounds - therapeutic use | Anxiety - drug therapy | Piperidones - therapeutic use | Serotonin - chemistry | Brain - metabolism | Pyridines - adverse effects | Fenclonine - adverse effects | Behavior, Animal - drug effects | Hyperkinesis - chemically induced | Neurons - metabolism | Serotonin 5-HT1 Receptor Antagonists - administration & dosage | Anti-Anxiety Agents - therapeutic use | Buspirone - therapeutic use | Fluoxetine - adverse effects | Disease Models, Animal | Pyridines - administration & dosage | Nerve Tissue Proteins - agonists | Piperazines - therapeutic use | Piperazines - adverse effects | Extracellular Fluid - drug effects | Brain - drug effects | Serotonin Uptake Inhibitors - administration & dosage | Fluoxetine - administration & dosage | Piperazines - administration & dosage | Fenclonine - therapeutic use | Spiro Compounds - administration & dosage | Piperidones - adverse effects | Hyperkinesis - metabolism | Spiro Compounds - adverse effects | Dose-Response Relationship, Drug | Buspirone - administration & dosage | Protein Isoforms - metabolism | Protein Isoforms - agonists | Anti-Anxiety Agents - adverse effects | Buspirone - adverse effects | Fluoxetine - therapeutic use | Neurons - drug effects | Anxiety - metabolism | Pyridines - therapeutic use | Nerve Tissue Proteins - antagonists & inhibitors | Serotonin Uptake Inhibitors - therapeutic use | Serotonin Uptake Inhibitors - adverse effects | Serotonin 5-HT1 Receptor Agonists - therapeutic use | Serotonin 5-HT1 Receptor Agonists - adverse effects | Serotonin 5-HT1 Receptor Antagonists - adverse effects | Nerve Tissue Proteins - metabolism | Piperidones - administration & dosage | Extracellular Fluid - metabolism | Serotonin 5-HT1 Receptor Antagonists - therapeutic use | Animals | Serotonin - metabolism | Serotonin 5-HT1 Receptor Agonists - administration & dosage | Anxiety - chemically induced | Protein Isoforms - antagonists & inhibitors | Phenols | Buspirone hydrochloride | Fluoxetine
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 11/2017, Volume 65, Issue 10, pp. 1711 - 1720
Background. Administration of artemisinin-based combination therapy (ACT) to infant and young children can be challenging. A formulation with accurate dose and... 
dispersible tablet | arterolane maleate | P. falciparum | pediatric | INFECTIOUS DISEASES | ADULTS | MICROBIOLOGY | IMMUNOLOGY | COMBINATION | ANTIMALARIAL | CHILDREN | PHARMACOKINETICS | DIHYDROARTEMISININ-PIPERAQUINE | ARTESUNATE PLUS AMODIAQUINE | Quinolines - blood | Ethanolamines - adverse effects | Artemisinins - pharmacokinetics | Tablets | Humans | Fluorenes - therapeutic use | Antimalarials - blood | Child, Preschool | Infant | Male | Spiro Compounds - therapeutic use | Peroxides - therapeutic use | Spiro Compounds - adverse effects | Peroxides - pharmacokinetics | Peroxides - adverse effects | Quinolines - pharmacokinetics | Ethanolamines - pharmacokinetics | Malaria, Falciparum - mortality | Artemisinins - blood | Female | Fluorenes - adverse effects | Fluorenes - blood | Child | Antimalarials - adverse effects | Fluorenes - pharmacokinetics | Malaria, Falciparum - drug therapy | Antimalarials - pharmacokinetics | Heterocyclic Compounds, 1-Ring - pharmacokinetics | Africa | Antimalarials - therapeutic use | Spiro Compounds - pharmacokinetics | India | Ethanolamines - blood | Peroxides - blood | Artemisinins - therapeutic use | Spiro Compounds - blood | Heterocyclic Compounds, 1-Ring - adverse effects | Survival Analysis | Heterocyclic Compounds, 1-Ring - therapeutic use | Ethanolamines - therapeutic use | Quinolines - therapeutic use | Heterocyclic Compounds, 1-Ring - blood | Artemisinins - adverse effects | Drug Combinations | Quinolines - adverse effects
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2014, Volume 371, Issue 5, pp. 403 - 410
Journal Article
Journal of Pharmacology and Experimental Therapeutics, ISSN 0022-3565, 2014, Volume 349, Issue 3, pp. 535 - 548
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 9/2012, Volume 55, Issue 5, pp. 663 - 671
Journal Article
Cancer, ISSN 0008-543X, 08/2016, Volume 122, Issue 15, pp. 2418 - 2425
BACKGROUND Rolapitant, a novel neurokinin‐1 receptor antagonist, provided effective protection against chemotherapy‐induced nausea and vomiting (CINV) in a... 
moderately emetogenic chemotherapy | chemotherapy‐induced nausea and vomiting | carboplatin | neurokinin‐1 receptor antagonist | rolapitant | Carboplatin | Moderately emetogenic chemotherapy | Rolapitant | Neurokinin-1 receptor antagonist | Chemotherapy-induced nausea and vomiting | GUIDELINE UPDATE | SAFETY | APREPITANT | neurokinin-1 receptor antagonist | CELL LUNG-CANCER | TRIAL | PATTERN | ONCOLOGY | DOUBLE-BLIND | EMESIS | chemotherapy-induced nausea and vomiting | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Spiro Compounds - therapeutic use | Spiro Compounds - adverse effects | Carboplatin - adverse effects | Neoplasms - complications | Aged, 80 and over | Adult | Female | Nausea - drug therapy | Vomiting - prevention & control | Neurokinin-1 Receptor Antagonists - adverse effects | Chemoprevention | Neurokinin-1 Receptor Antagonists - therapeutic use | Risk Factors | Carboplatin - administration & dosage | Neoplasms - mortality | Treatment Outcome | Vomiting - drug therapy | Neoplasms - drug therapy | Nausea - prevention & control | Nausea - etiology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vomiting - etiology | Aged | Complications and side effects | Care and treatment | Chemotherapy | Nausea | Dosage and administration | Cancer | Original
Journal Article
Journal Article
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2016, Volume 57, pp. 23 - 30
Abstract Objective Rolapitant, a novel neurokinin-1 receptor antagonist (RA), was shown to protect against delayed chemotherapy-induced nausea and vomiting... 
Hematology, Oncology and Palliative Medicine | Multiple cycles | Rolapitant | Neurokinin-1 receptor antagonist | Antiemetic | Chemotherapy-induced nausea and vomiting | Subsequent cycles | DEXAMETHASONE | PHASE-III | APREPITANT | ORAL NK1 ANTAGONIST | CANCER | RECEPTOR ANTAGONIST | CISPLATIN-BASED CHEMOTHERAPY | PHARMACOKINETICS | ONCOLOGY | DOUBLE-BLIND | ANTIEMETICS PROVIDES PROTECTION | Granisetron - administration & dosage | Nausea - chemically induced | Humans | Middle Aged | Antiemetics - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Spiro Compounds - administration & dosage | Male | Spiro Compounds - adverse effects | Serotonin 5-HT3 Receptor Antagonists - administration & dosage | Young Adult | Clinical Trials, Phase III as Topic | Aged, 80 and over | Adult | Antiemetics - adverse effects | Female | Drug Therapy, Combination | Vomiting - prevention & control | Granisetron - adverse effects | Dexamethasone - administration & dosage | Neurokinin-1 Receptor Antagonists - adverse effects | Double-Blind Method | Administration, Oral | Ondansetron - administration & dosage | Neurokinin-1 Receptor Antagonists - administration & dosage | Treatment Outcome | Neoplasms - drug therapy | Randomized Controlled Trials as Topic | Nausea - prevention & control | Retreatment | Vomiting - chemically induced | Aged | Ondansetron - adverse effects | Clinical Trials, Phase II as Topic | Prevention | Medical colleges | Chemotherapy | Nausea | Analysis | Cancer | Index Medicus
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 11/2015, Volume 23, Issue 11, pp. 3281 - 3288
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 03/2014, Volume 54, Issue 3, pp. 351 - 357
TRV130 is a G protein‐biased ligand at the µ‐opioid receptor. In preclinical studies it was potently analgesic while causing less respiratory depression and... 
TRV130 | analgesic | opioid | biased ligand | PRACTICE GUIDELINES | MORPHINE | PHARMACOLOGY & PHARMACY |